vTv Therapeutics Inc. - (VTVT): Price and Financial Metrics

vTv Therapeutics Inc. - (VTVT): $24.25

0.10 (+0.41%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add VTVT to Watchlist
Sign Up

VTVT Price/Volume Stats

Current price $24.25 52-week high $39.60
Prev. close $24.15 52-week low $7.38
Day low $24.00 Volume 2,417
Day high $24.25 Avg. volume 64,537
50-day MA $17.93 Dividend yield N/A
200-day MA $17.61 Market Cap 72.99M

VTVT Stock Price Chart Interactive Chart >


vTv Therapeutics Inc. - (VTVT) Company Bio


vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina.


VTVT Latest News Stream


Event/Time News Detail
Loading, please wait...

VTVT Latest Social Stream


Loading social stream, please wait...

View Full VTVT Social Stream

Latest VTVT News From Around the Web

Below are the latest news stories about VTV THERAPEUTICS INC that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. “Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on

Yahoo | November 9, 2023

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief Financial Officer, Steven Tuch, its Chief Scientific Officer, Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will be presenting at the Stifel 2023 Healthcare Conference on November 15,

Yahoo | November 8, 2023

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutic

Yahoo | November 2, 2023

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that it has entered into a common stock repurchase agreement with Reneo Pharmaceuticals, Inc. through which Reneo has purchased all of its common stock that was granted to vTv under the Reneo License Agreement for to

Yahoo | November 1, 2023

One vTv Therapeutics Insider Raised Their Stake In The Previous Year

From what we can see, insiders were net buyers in vTv Therapeutics Inc.'s ( NASDAQ:VTVT ) during the past 12 months...

Yahoo | October 19, 2023

Read More 'VTVT' Stories Here

VTVT Price Returns

1-mo 16.03%
3-mo 189.03%
6-mo 40.99%
1-year -20.23%
3-year -75.05%
5-year -53.54%
YTD 110.87%
2023 -56.62%
2022 -33.39%
2021 -46.51%
2020 9.41%
2019 -35.85%

Continue Researching VTVT

Want to see what other sources are saying about vTv Therapeutics Inc's financials and stock price? Try the links below:

vTv Therapeutics Inc (VTVT) Stock Price | Nasdaq
vTv Therapeutics Inc (VTVT) Stock Quote, History and News - Yahoo Finance
vTv Therapeutics Inc (VTVT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!